Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity
The Inside Story of Ozempic and the Race to Cure Obesity
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity
Buy Now for $21.99
-
Narrated by:
-
Yael Rizowy
-
By:
-
Aimee Donnellan
About this listen
The inside story of the race to develop Ozempic – the world’s first truly effective and safe obesity drug – and its potentially revolutionary effects on public health, and our deeper culture and values.
'ENLIGHTENING' Publishers Weekly
A ‘cure’ for obesity has long evaded the pharmaceutical industry, until the development of Ozempic: a diabetes medication that targets the GLP-1 hormone and makes people feel fuller for longer.
After decades of research, Ozempic’s creator Novo Nordisk quickly became one of the most valuable companies in Europe. Now it struggles to keep up with its rivals in an explosive and lucrative market for weight-loss injections. The treatment is so effective that it’s already disrupted industries from healthcare to fast food to fashion. Financial investment has skyrocketed and public demand continues to soar alongside celebrity endorsements. Beyond million-dollar profits, countless lives could now be saved from preventable diseases, but one question remains: are these drugs too good to be true?
Through original reporting and rigorous research, Aimee Donnellan uncovers the complicated history of a medical breakthrough that is changing the world, while raising difficult questions about inequality, morality, our beauty ideals and the pursuit of thinness. Along the way, Donnellan profiles the female scientist whose contributions to the discovery of GLP-1 were overlooked and some of the earliest Ozempic users share powerful testimonies.
Off the Scales is a revelatory, gripping and urgent study of the unexpected consequences of finally getting what we’ve wanted for so long.
'The definitive account of a singular global force – essential reading to help us understand what has been unleashed and what may be coming next' Andy Slavitt, author of Preventable
'A riveting and impeccably researched deep-dive into the murky world of drug development' Josie Cox, author of Women Money Power
'Donnellan captures the drama behind the science … and explores the wider implications for society, health and business in this deeply researched book' John Collingridge, Guardian business editor
©2025 Aimee Donnellan (P)2025 Macmillan AudioCritic Reviews
'Ultimately, the book presents a scathing critique of the big corporations that have shamelessly leveraged people’s insecurities to get rich, and offers a mixed prognosis for the future: Ozempic may hold a world of promise, but there could be a far darker side that we’re only just starting to see' Josie Cox, author of Women Money Power
'Off the Scales captures the many facets of this fast-moving story, including the decades of scientific research that led to their creation, the stories of early patients and the culture change required to understand obesity as a medical condition rather than a character flaw. Donnellan is a gifted storyteller who brings complicated subjects to life and offers a hopeful vision for how these therapies are transforming lives and reshaping our approach to health care' Leana Wen, M.D., author of Lifelines
'A riveting read about one of the most important medical advances of our time. Aimee Donnellan captures the drama behind the science, the cast of characters who devoted their lives to it, the cut-throat world of drug development and explores the wider implications for society, health and business in this deeply researched book' John Collingridge, Guardian business editor
'A tangled plot stuffed with big money, towering egos, and innovative science, capably told and without an ounce of flab … “The potential ripple effects of this healthcare revolution are difficult to overstate,” Donnellan comments, and she makes this abundantly clear in her rich, even action-packed narrative of medical discovery' Kirkus Review
'[An] enlightening debut history of Ozempic and its societal impact … Donnellan cogently sizes up its future potential: GLP-1 could lead to a healthier population empowered to demand healthier foods and living conditions, or it could further expand the gulf between rich and poor. It makes for an astute, fair-minded primer on the drug’ Publishers Weekly